Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Comirnaty Bags Special Approval in Japan for Kids Aged 6 Months to 4 Years
Pfizer’s COVID-19 vaccine Comirnaty gained the regulatory nod in Japan on October 5 for use in children between the ages of six months and four years. This is the first COVID-19 jab to be approved in the country for children…
To read the full story
Related Article
- Pfizer’s Bivalent COVID Vaccines Approved for Primary Series in Japan
August 3, 2023
- BA.4/5-Based Jab Filed for 6 Months to 4 Years in Japan: Pfizer/BioNTech
April 12, 2023
- Japan to Roll Out BA.4/5 Omicron Boosters on Oct. 13, Inoculations for 6 Months to 4 Years from Oct. 24
October 11, 2022
- MHLW Panel to Discuss Shortening of COVID Booster Interval
October 11, 2022
- Pfizer’s BA.4/5-Adapted Comirnaty Grabs Special Approval in Japan
October 6, 2022
- Japan Panel to Discuss Comirnaty for Kids Aged 6 Months to 4 Years on Oct. 5
September 29, 2022
- Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
September 13, 2022
- Pfizer Japan Files COVID-19 Vaccine for Ages 6 Months to 4 Years
July 15, 2022
REGULATORY
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
- HHS Report Puts Japan’s Drug Innovation Financing Well Behind US
July 15, 2026
- MHLW Orders Label Revisions for PPIs, Checkpoint Inhibitors
July 15, 2026
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…